ORIGINAL ARTICLE   Free access

Italian Journal of Dermatology and Venereology 2023 June;158(3):249-54

DOI: 10.23736/S2784-8671.23.07605-3

Copyright © 2023 EDIZIONI MINERVA MEDICA

lingua: Inglese

Pso-Reg: a web registry for psoriasis in real life

Emanuele TROVATO ¹, Alessandra CARTOCCI ^{1, 2} ✉, Laura CALABRESE ^{1, 3}, Martina D’ONGHIA ¹, Martina DRAGOTTO ¹, Eugenio CAPALBO ¹, Gianmarco SILVI ⁴, Flavia MANZO MARGIOTTA ⁵, Nicola PIMPINELLI ⁴, Michele PELLEGRINO ⁶, Marco ROMANELLI ⁵, Valentina DINI ⁵, Aldo CUCCIA ⁷, Carlo MAZZATENTA ⁸, Pietro RUBEGNI ¹, Francesca PRIGNANO ⁴

¹ Unit of Dermatology, Department of Medical, Surgical and Neurological Science, University of Siena, Siena, Italy; ² Department of Medical Biotechnologies, University of Siena, Siena, Italy; ³ Institute of Dermatology, Sacred Heart Catholic University, Rome, Italy; ⁴ Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy; ⁵ Department of Dermatology, University of Pisa, Pisa, Italy; ⁶ Unit of Dermatology, Misericordia Hospital, Grosseto, Italy; ⁷ Unit of Dermatology, San Donato Hospital, Arezzo, Italy; ⁸ Unit of Dermatology, Campo di Marte Hospital, Lucca, Italy

BACKGROUND: Psoriasis (PsO) is a common immune mediated inflammatory disease, affecting about 60 million people worldwide. Although current therapies have dramatically changed the therapeutic approach to the disease, the heterogeneity of responses often results in an essential unmet clinical need. This study describes the design and development of the Psoriasis Registry (Pso-Reg), an Italian electronic-based-registry, aimed to collect real life data of patients with psoriasis.
METHODS: Pso-Reg is a multicenter, retrospective and observational cohort study based on the Research Electronic Data Capture (REDcap) tool. Five Italian medical centres were part of the network and all patients affected by PsO were included in the study. Socio-demographic, clinical characteristics, laboratory findings and therapies were collected, and descriptive analysis was carried out.
RESULTS: Among the 768 patients analyzed, 446 were men (58.1%), with a mean age of 55.5 years. The first more frequent comorbidity was psoriatic arthritis (26.8%), followed by hypertension (25.3%), diabetes (10%) and dyslipidemia (11.7%). Of the entire cohort, 240 patients (38.2%) had a positive family history for PsO. Vulgar type was the most common phenotype (85.5%), with a major involvement of the scalp (13.8%). The mean PASI (Psoriasis Area Severity Index) score at the baseline was 7.5 (7.8). At the enrolment, 107 patients were treated with topic treatments (13.9%), 5 with phototherapy (0.7%), 92 with cDMARDs (conventional disease-modifying anti-rheumatic drugs) (12.0%) and 471 with biologic therapies (61.3%).
CONCLUSIONS: Real-life data from Pso-Reg could contribute providing the rationale for an individual-based strategy and a more tailored approach for the management of psoriasis.

KEY WORDS: Psoriasis; Epidemiology; Dermatology; Evidence-based medicine